These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23308105)

  • 21. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
    Chen SF; Shen YC; Chen CH
    Psychopharmacology (Berl); 2009 Aug; 205(2):285-92. PubMed ID: 19387614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
    Volavka J; Czobor P; Citrome L; McQuade RD; Carson WH; Kostic D; Hardy S; Marcus R
    J Clin Psychiatry; 2005 Nov; 66(11):1362-6. PubMed ID: 16420071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.
    Korostenskaja M; Dapsys K; Siurkute A; Maciulis V; Ruksenas O; Kähkönen S
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):543-8. PubMed ID: 15866356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.
    Pae CU; Chiesa A; Mandelli L; Patkar AA; Gibiino S; Serretti A
    Clin Drug Investig; 2010; 30(3):187-93. PubMed ID: 20155991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia.
    Lee SH; Sung K; Lee KS; Moon E; Kim CG
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():213-9. PubMed ID: 24161665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
    Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
    Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
    Riedel M; Spellmann I; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Severus E; Engel RR; Müller N; Möller HJ
    Pharmacopsychiatry; 2010 Mar; 43(2):50-7. PubMed ID: 20336597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
    Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified 'optimal' multi-feature paradigm.
    Fisher DJ; Grant B; Smith DM; Borracci G; Labelle A; Knott VJ
    Int J Psychophysiol; 2011 Sep; 81(3):245-51. PubMed ID: 21749905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of auditory and visual training on the mismatch negativity in schizophrenia.
    Kärgel C; Sartory G; Kariofillis D; Wiltfang J; Müller BW
    Int J Psychophysiol; 2016 Apr; 102():47-54. PubMed ID: 26968496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm.
    McCleery A; Mathalon DH; Wynn JK; Roach BJ; Hellemann GS; Marder SR; Green MF
    Psychol Med; 2019 May; 49(7):1195-1206. PubMed ID: 30642411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis.
    Hamilton HK; Roach BJ; Bachman PM; Belger A; Carrión RE; Duncan E; Johannesen JK; Light GA; Niznikiewicz MA; Addington J; Bearden CE; Cadenhead KS; Cornblatt BA; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Cannon TD; Mathalon DH
    JAMA Psychiatry; 2022 Aug; 79(8):780-789. PubMed ID: 35675082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis.
    Nagai T; Tada M; Kirihara K; Yahata N; Hashimoto R; Araki T; Kasai K
    Schizophr Res; 2013 Nov; 150(2-3):547-54. PubMed ID: 24012461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The right profile: mismatch negativity in schizophrenia with and without auditory hallucinations as measured by a multi-feature paradigm.
    Fisher DJ; Labelle A; Knott VJ
    Clin Neurophysiol; 2008 Apr; 119(4):909-21. PubMed ID: 18261954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
    Marder SR; West B; Lau GS; Pultz JA; Pikalov A; Marcus RN; Gutierrez-Esteinou R; Crandall DT
    J Clin Psychiatry; 2007 May; 68(5):662-8. PubMed ID: 17503974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.